dockets: FDA-2007-P-0188
Data license: Public Domain (U.S. Government data) · Data source: U.S. government sources, plus a few identifier registries; each is listed on the methodology page
This data as json
| id | agency_id | title | docket_type | last_modified | object_id | rin | dkabstract | category | subtype | keywords | program | short_title | effective_date | organization | attrs_raw | attr_source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-P-0188 | FDA | Determine Whether a Food-Effect Study Should be Required as Part of the Demonstration of Bioequivalence for Clozapine Orally Disintegrating Tablets (ODT), 100 mg | Nonrulemaking | 2021-09-01T01:01:02Z | 0b0000648042a75c | Docket Status: CLOSED per Petition Denial Letter dtd 5/6/2015 | ["orally", "fazaClo", "100 mg", "odt", "disintegrating tablets", "clozapine", "bioequivalence", "food-effect", "CDER", "closed"] | CDER | Determine whether a food-effect study should be required as part of the demonstration of bioequivalence for clozapine orally disintegrating tablets (ODT), 100 mg | {"displayProperties": [{"name": "abstract", "label": "General Information", "tooltip": "Describes an agency's specific regulatory action; equivalents: Abstract, Description, Docket Subject, Related To, Summary."}, {"name": "legacyId", "label": "Legacy ID", "tooltip": "A pre-FDMS agency specific identifier migrated from a legacy system."}, {"name": "generic", "label": "Docket Item Code", "tooltip": "An agency specific code that identifies the type of document that established the docket (regulatory action)."}, {"name": "program", "label": "Center", "tooltip": "The agency specific program associated with the docket (regulatory action); equivalents: Docket Item Code, Location."}, {"name": "field2", "label": "Docket Status", "tooltip": "Used to Identity that a Docket's Status is Open or Closed"}, {"name": "shortTitle", "label": "Short Title", "tooltip": "A combination of letters and or numbers assigned to an agency's regulatory action for purposes of brevity."}], "keywords": ["orally", "fazaClo", "100 mg", "odt", "disintegrating tablets", "clozapine", "bioequivalence", "food-effect", "CDER", "closed"], "modifyDate": "2021-09-01T01:01:02Z", "dkAbstract": "Docket Status: CLOSED per Petition Denial Letter dtd 5/6/2015", "agencyId": "FDA", "program": "CDER", "shortTitle": "Determine whether a food-effect study should be required as part of the demonstration of bioequivalence for clozapine orally disintegrating tablets (ODT), 100 mg", "subType2": null, "title": "Determine Whether a Food-Effect Study Should be Required as Part of the Demonstration of Bioequivalence for Clozapine Orally Disintegrating Tablets (ODT), 100 mg", "generic": "P", "field1": null, "docketType": "Nonrulemaking", "petitionNbr": null, "rin": null, "organization": null, "legacyId": "2007P-0499", "subType": null, "category": null, "field2": "CLOSED", "effectiveDate": null, "objectId": "0b0000648042a75c"} | single_get |
Links from other tables
- 6 rows from docket_id in documents